Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label mass balance study of 14C-JNJ-40411813 in healthy male participants
NL-OMON51781Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of adx-71149 in epilepsy, anxiety disorder and schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma concentrations of JNJ-40411813 and metabolites, Total radioactivity in plasma and whole blood and 3 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
adx-71149
03
Conditions
epilepsyanxiety disorderschizophrenia
Beyond the preview
Go deeper on NL-OMON51781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51781.